Screener
NewAmsterdam Pharma Company NAMS Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -3,432.2%-3,162pp | -953.6%-551pp | -1,002.9%-616pp | -575.8%-27.7pp | -270%+2,541pp | |
| Net margin | -3,644.2%-3,385pp | -942.8%-545pp | -905.7%-375pp | -627.3%-35.2pp | -258.9%+2,831pp | |
| Returns | ||||||
| Return on equity | -36.8%-8.4pp | -29.5%+2.0pp | -28.3%+17.9pp | -39.9%+16.0pp | -28.4%+31.9pp | |
| Return on invested capital | -115.7%— | -181.6%— | —— | —— | —— | |
| Efficiency | ||||||
| Asset turnover | 0×-0.1× | 0×0.0× | 0×0.0× | 0.1×— | 0.1×— | |
| Liquidity | ||||||
| Current ratio | 9×-12.1× | 9.8×-10.2× | 7.9×-0.2× | 12.6×+2.0× | 21.1×+11.3× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Valuation | ||||||
| Market capitalization | $3.31B+24.7% | $3.68B+63.7% | $3.98B+44.6% | $3.2B+114% | $2.07B+19.5% | |
| Price / sales | 464.5×+423× | 163.1×+115× | 176.8×+116× | 90.9×+46.4× | 32.3×-201× | |
| Price / book | 5.2×+1.8× | 5.5×+2.6× | 5.8×+2.2× | 4.4×+0.5× | 2.7×-1.8× |
FAQ
- Where do NewAmsterdam Pharma Company's ratios come from?
- Every ratio is computed from NewAmsterdam Pharma Company's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
